Figure 2.

BRCA2 siRNA induces complementary lethality to treatment with cisplatin, melphalan and 5-FUdR, but not pemetrexed. A549 cells were transfected with control siRNA (black bars) or BRCA2 siRNA (white bars) and treated with (a) cisplatin (IC₂₅), (b) melphalan (IC₂₅), (c) 5-FUdR (IC₂₅), or (d) pemetrexed (IC₂₅). HeLa cells were treated under the same conditions and with (e–h) the same drugs. Effects on cell growth were assessed 96 hours after transfection, as a percentage of cells treated with control nontargeting siRNA alone. *Different from treatment with control siRNA alone (Student's t-test, P < 0.05). **Different from treatment with drug and control siRNA (Student's t-test, P < 0.05). Representative data from one of three independent experiments is shown (mean ± SD).